AbbVie unveils blood cancer advancements as stock holds near highs despite mild pullback

Traders Union
All News
Companies
AbbVie slides 0.48% today

Highlights

ABBV maintains a bullish technical setup, trading above all major trend indicators across short and long-term timeframes.
Momentum signals show overbought conditions and mild trend strength, suggesting buyers remain active but upside is limited.
Price is consolidating near record highs, with a likely trading range between $229.00 and $232.50 next week and low probability of a breakout.

Bullish trend confirmed as price holds above key moving averages

ABBV is currently trading at $226.14, which is above the MA-20 ($213.49), MA-50 ($209.60), and MA-200 ($219.95), confirming a robust bullish structure across short, medium, and long-term trends. The Ichimoku Kijun on D1 stands at $215.31, acting as immediate support; near-term support is seen at MA-200 ($219.95), with key support at MA-100 ($215.89), while immediate resistance is at MA-5 ($219.53) and key resistance at MA-20 ($213.49).

Overbought signals emerge as buyers consolidate near weekly highs

Momentum indicators on D1 are largely bullish, with MACD and ADX suggesting buyer dominance, though the ADX value signals a mild trend. RSI (68.96), CCI, Stoch RSI, and BBP all indicate overbought conditions, with BBP showing strong buyer pressure. The Awesome Oscillator is aligned with upbeat momentum. ABBV is trading at $226.14, down from the weekly open of $227.23, slipping 0.53% over the week and currently positioned at the very top of its weekly range. Weekly volatility stands at 10.25%. The tone this week reflects consolidation at elevated levels after testing the weekly high.

Sideways bias likely as weekly signals remain mixed

For the upcoming week, ABBV is expected to trade in a range between $229.00 and $232.50, keeping the forecast within roughly ±3% of the current price and referencing the 52-week boundaries of $181.73 and $244.81. The probability of a further price increase is very low (less than 20%) based on conflicting W1 signals—RSI and MA-50 remain bullish, but MACD on W1 suggests a strong sell and ADX is neutral, making a renewed advance unlikely. The baseline scenario calls for ABBV to consolidate sideways near its current highs. A bullish scenario could materialize if it breaks above $232.50, targeting the previous annual high. A bearish scenario would see a retracement to $219.95 if the price falls below immediate support, with deeper downside toward $215.89 if selling intensifies.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that AbbVie’s stock demonstrated notable upward momentum amid positive drug approval news and expanding market opportunities. In the context of current developments, investors should closely monitor whether this momentum persists, with particular attention to any technical shift that could signal a near-term change in the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.